Literature DB >> 17583752

Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin.

Jian Yang1, Jack Campitelli, Gang Hu, Yanhe Lin, Jin Luo, Chun Xue.   

Abstract

High fat diet or insulin deficiency is commonly seen in Type II diabetes, while the mechanism remains unclear. To test our hypothesis that DPP-IV contributes to Type II diabetes, we examined the expression and activity of DPP-IV in rats (n=8 to each group) treated for 12 weeks with 3 separate diets: a) normal control; b) a high fat diet; and c) a high fat diet plus streptozotocin, a chemical for induction of insulin-deficient diabetes. Compared to rats on the normal diet, the rats with a high fat diet significantly increased DPP-IV's expression and activity about 142-152% in the intestine (P<0.05) and 153-240% in kidneys (P<0.05), but there was no change in the liver. Administration of streptozotocin to the rats treated with the high fat diet showed an insufficient insulin secretion and higher blood glucose in response to glucose/insulin tolerance test, and an increase in expression of DPP-IV and activity by 188-242% in the intestine (P<0.01); 191-225% in liver (P<0.01); and 211-321% in the kidneys (P<0.01). Immunohistochemistry studies confirmed the above results, showing increased DPP-IV immunostaining localized primarily in intestinal epithelium, hepatocytes and renal tubular cells. This study, for the first time reports an increase in DPP-IV associated with a high fat diet, as well as in the combination of a high fat diet with an insulin deficiency. Since both high fat diet and insulin deficiency are closely linked with etiology of Type II diabetes, the evidence in this study suggests a role of DPP-IV in development of Type II diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583752     DOI: 10.1016/j.lfs.2007.04.040

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  29 in total

1.  Nutrient-specific feeding and endocrine effects of jejunal infusions in obese animals.

Authors:  Megan J Dailey; Alexander A Moghadam; Timothy H Moran
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-22       Impact factor: 3.619

Review 2.  Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Authors:  Hubert Zatorski; Maciej Sałaga; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-29       Impact factor: 3.000

3.  DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.

Authors:  Jee Eun Lee; Jung Eun Kim; Mi Hwa Lee; Hye Kyoung Song; Jung Yeon Ghee; Young Sun Kang; Hye Sook Min; Hyun Wook Kim; Jin Joo Cha; Jee Young Han; Sang Youb Han; Dae Ryong Cha
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

Review 4.  Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.

Authors:  Annayya R Aroor; James R Sowers; Guanghong Jia; Vincent G DeMarco
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-15       Impact factor: 4.733

Review 5.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

Review 6.  Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease.

Authors:  Ramiro A Sanchez; Hugo Sanabria; Cecilia de Los Santos; Agustin J Ramirez
Journal:  World J Diabetes       Date:  2015-09-10

Review 7.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

Review 8.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

Review 9.  The evolving place of incretin-based therapies in type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Pediatr Nephrol       Date:  2010-02-04       Impact factor: 3.714

10.  Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.

Authors:  Timo Rieg; Maria Gerasimova; Fiona Murray; Takahiro Masuda; Tong Tang; Michael Rose; Daniel J Drucker; Volker Vallon
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.